Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elena Ocher

Anesthesiology Forest Hills, NY Medical Doctor

NPI 1770589335 CMS profile 216146

112-47 Queens Blvd Suite 204, Forest Hills, NY 11375

Open in the dashboard

General payments

$7,157

375 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elena Ocher of Forest Hills, NY is reported in the CMS Open Payments database as having received $7,157 across 375 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $633 24
2024 General $936 44
2023 General $1,368 65
2022 General $1,221 59
2021 General $1,142 73
2020 General $474 34
2019 General $1,383 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elena Ocher
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Elena Ocher were reported at $633. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Elena Ocher Anesthesiology median Middle half National median
2019 $1,383 $72 $23–$151 $163
2020 $474 $36 $17–$120 $114
2021 $1,142 $49 $21–$135 $132
2022 $1,221 $52 $22–$144 $149
2023 $1,368 $53 $23–$143 $160
2024 $936 $55 $25–$150 $164
2025 $633 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,919 140 payments
  2. Allergan Inc. $463 39 payments
  3. Pfizer Inc. $354 18 payments
  4. Boston Scientific Corporation $275 9 payments
  5. Daiichi Sankyo Inc. $271 25 payments
  6. Biohaven Pharmaceuticals, Inc. $247 16 payments
  7. Amgen Inc. $242 10 payments
  8. Nevro Corp. $239 7 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $184 12 payments
  10. Almatica Pharma LLC $165 8 payments
  11. Other $1,797 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,157 375 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,284 73 payments
  2. QULIPTA $1,122 53 payments
  3. BOTOX Hyperhydrosis $533 43 payments
  4. NURTEC ODT Primary Care $432 28 payments
  5. AIMOVIG $381 17 payments
  6. BOTOX Neuroscience $350 9 payments
  7. NURTEC ODT Pain $337 17 payments
  8. BOTOX Botox Therapeutic $293 12 payments
  9. ZAVZPRET $213 10 payments
  10. Movantik $202 20 payments
  11. Other $2,825 136 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,437

Median for Anesthesiology: 322

Drug cost

$101,829

Median for Anesthesiology: $8,738

Branded share of claims

32.2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 30 $38,539
Diclofenac Sodium Generic 53 $20,984
Ztlido Lidocaine Brand 37 $12,699
Ozempic Semaglutide Brand 13 $11,502
Oxycodone Hcl Generic 164 $3,730
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 232 $3,615
Fentanyl Generic 33 $1,413
Gabapentin Generic 174 $1,318
Methadone Hcl Generic 103 $1,094
Lidocaine Generic 12 $916

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$319,306

Of which drugs: $22,447

Medicare patients

263

Average age 75

Services billed

8,962

182 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 55%
Ischemic heart disease 49%
Depression 35%
Osteoporosis 23%
Heart failure 22%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 14 3,070 $14,751
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 33 86 $4,956
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 217 1,589 $1,197
Infusion, normal saline solution , 1000 cc J7030 Office 141 531 $1,088
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 83 266 $274
Injection, cefazolin sodium, 500 mg J0690 Office 45 113 $68
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 16 60 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $268
$268 30 3,070
UBRELVY
  • AbbVie, Inc. $224
$224 — —
QULIPTA
  • AbbVie, Inc. $194
$194 — —
VYEPTI
  • Lundbeck LLC $89
$89 — —
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

375 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record